Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Supplement caucus vows to protect industry

This article was originally published in The Tan Sheet

Executive Summary

Reps. Dan Burton, R-Ind., and Jared Polis, D-Colo., both Congressional Dietary Supplement Caucus co-chairs, reaffirm their support for the supplement industry and say they will work to minimize government intervention. "One of the things I'm concerned about is that we make absolutely sure that government intervention in the supplement industry is absolutely minimal," Burton said during a Nov. 4 briefing on sports nutrition and dietary supplements held by the Council for Responsible Nutrition and the Natural Products Association. "I don't want the pharmaceutical industry or any other industry trying to do away with [the Dietary Supplement Health and Education Act] and take over the supplement industry," he added. Burton said he, Polis and other caucus members want "to do everything we can to make sure that [the supplement industry] remains as independent of the government as much as possible.

You may also be interested in...

Faster, Better? Fujitsu, Polarisqb 'Quantum-Inspired' Tech Speeds Discovery

Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.

Keeping Track: Oncology Submissions From Blueprint, Y-mAbs, BMS/bluebird; Approvals For BMS’ Reblozyl, LFB’s SevenFact

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.

Part B Drugs At Home: Medicare Policy Responds To COVID-Driven Access Concerns

Temporary policy may open door to longer term change as Medicare allows reimbursement of at-home administration of non-hospital drugs covered by Part B under a recently-released regulation aiding at encouraging telehealth during the coronavirus outbreak.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts